ULSS3 SERENISSIMA - Ospedale dell'Angelo di Mestre

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Acute lymphoblastic leukaemia5 trials
• Acute myeloid leukaemia4 trials
• Chronic myeloid leukaemia1 trial

Phase

• Phase 27 trials
• Phase 33 trials

Status

• Active, not recruiting5 trials
• Recruiting4 trials
• Completed1 trial

Lead sponsor

• Gruppo Italiano Malattie EMatologiche dell'Adulto7 trials
• Fondazione G.I.M.Em.A Franco Mandelli Ets2 trials
• Fondazione Gimema Franco Mandelli Onlus1 trial

Running trials

• Recruiting

  PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

  NCT06409936· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Not yet recruiting

  Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

  NCT06667973· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Active, not recruiting

  Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program

  NCT06253637· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Active, not recruiting

  Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

  NCT05306301· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Active, not recruiting

  Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients suffering from Acute Myeloid Leukemia with NPM1 mutation.

  NCT04867928· Phase 2· Fondazione G.I.M.Em.A Franco Mandelli Ets· Source

• Active, not recruiting

  Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

  NCT04722848· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Recruiting

  Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

  NCT04168502· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Recruiting

  Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to customize therapy.

  NCT04174612· Phase 3· Fondazione G.I.M.Em.A Franco Mandelli Ets· Source

• Active, not recruiting

  Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

  NCT03610438· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia3 recruiting
• Acute lymphoblastic leukaemia1 recruiting

Closed trials

• Completed

  The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in patients: MRD positive (persistent or relapsed), patients after haematological and extra-haematological relapse and patients who do not have never achieved remission after any previous treatment.

  NCT04475731· Phase 2· Fondazione Gimema Franco Mandelli Onlus· Source